FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to crystalloid cardioplegic solution, which contains sodium chloride, potassium chloride, calcium chloride, magnesium sulphate, glucose, dihydroorthophosphate-anion, bicarbonate-anion, sulphate-anion, and water, with the following ingredient ratio, mmol/l: sodium 143; potassium 25; magnesium 16; calcium 0.3; bicarbonate-anion 25; dihydroorthophosphate-anion 1.2; glucose 11; chlorine-anion 142.1; sulphate-anion 16; distilled water 1 l.
EFFECT: solution is intended for protection of heart from global ischemia during cardio-surgical operations and has improved cardio-protecting properties.
6 tbl
Title | Year | Author | Number |
---|---|---|---|
CARDIOPLEGIA AGENT (VERSIONS) | 2014 |
|
RU2568911C1 |
CRYSTALLOID CARDIOPLEGIC SOLUTIONS, CONTAINING DODECAPEPTIDES (VERSIONS) | 2013 |
|
RU2549470C1 |
METHOD FOR CARDIOPLEGIC ARREST (VERSIONS) | 2015 |
|
RU2571058C1 |
"INFUSOL" CARDIOPLEGIC SOLUTION | 2002 |
|
RU2226093C1 |
METHOD OF MYOCARDIUM PROTECTION DURING OPERATIONS ON HEART | 2004 |
|
RU2335290C2 |
METHOD FOR RESTORING HEART CONTRACTILITY AFTER CARDIOPLEGIA WITH CALCIUM ANTAGONISTS IN EXPERIMENT | 1996 |
|
RU2133612C1 |
METHOD OF CARDIOPLEGIC ANTEGRADE MYOCARDIAL PROTECTION | 2022 |
|
RU2803867C1 |
CARDIOPLEGIC SOLUTION (VERSIONS) | 2014 |
|
RU2574957C1 |
METHOD FOR EVALUATING THE STATE OF MYOCARDIUM IN CARDIOSURGICAL INTERVENTIONS UNDER CONDITIONS OF CARDIOPLEGIC PROTECTION | 2017 |
|
RU2651364C1 |
METHOD OF MYOCARDIUM PRECONDITIONING IN OPERATIONS UNDER CONDITIONS OF ARTIFICIAL BLOOD SUPPLY | 2012 |
|
RU2504336C1 |
Authors
Dates
2011-07-10—Published
2009-07-08—Filed